Biotech VC Funds

BlueOcean Ventures is a Geneva, Switzerland-based venture capital firm founded in 2007 by four partners — Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz, and Thomas Zehnder — who collectively bring decades of experience building, managing, and coaching high-tech startups. The firm concentrates exclusively on early-stage medical device and life science companies across Europe, deploying check sizes of $1 million to $5 million at seed and early stages across 23 investments to date. BlueOcean leads rounds and has backed companies spanning healthtech, biotech, and diagnostic robotics. Fund II — which became the first tokenized medtech VC fund through its STO platform SwissVCToken — invested in five companies: Ava (named Switzerland's best startup in 2017/2018), Rheon Medical (adjustable glaucoma drainage device), Volumina Medical, Luciole Medical, and Abionic. Other portfolio companies include MIKAJAKI (ophthalmic diagnostic robotics, CHF 2.4M+ pre-Series A), nPloy, and CyanoGuard. Co-founder Sacha Haymoz previously co-founded PharmARC, a 300-person firm sold to IMS Health in 2012; Emmanuel de Watteville has coached over 200 high-tech startups since 2003. BlueOcean Ventures targets untapped market segments where capital scarcity and clinical complexity create a barrier that experienced domain partners can bridge. The firm supports portfolio companies with an extensive expert network and industry contacts, aiming to place capital where it addresses unmet medical needs rather than crowded, well-funded niches.

BlueRun Ventures (BRV), founded in 1998 and headquartered in Menlo Park, CA, is an early-stage venture capital firm with a global presence. The firm has offices in the United States, China (Beijing and Shanghai), and South Korea. BRV is known for its focus on mobile, fintech, digital health, and consumer experiences, targeting startups that solve significant problems in these sectors. BRV's portfolio boasts notable investments including PayPal, Waze, Coupa, and Kabbage, showcasing their track record in identifying and nurturing high-potential companies. The firm’s investment strategy involves leading seed and Series A rounds, typically investing between $2 million and $8 million per deal. They prioritize early-stage companies that exhibit strong growth potential and innovative solutions. The BRV team consists of experienced professionals such as co-founders John Malloy and Jonathan Ebinger, who bring deep expertise in mobile software, services, and financial technology. The team leverages its collective experience in product development, marketing, and design to support portfolio companies. Startups looking to engage with BRV should emphasize their potential for disruption and scalability. The firm values entrepreneurs who are pushing industry boundaries and can benefit from BRV’s extensive network and hands-on approach to growth.

BlueYard Capital is a venture capital firm that invests in early-stage companies with transformative potential across various industries. Established to support innovative founders, BlueYard focuses on creating a future where markets are open and decentralized, significant planetary challenges are addressed, and knowledge and data are liberated. The firm is known for its thematic investments in sectors like blockchain, crypto, artificial intelligence, web3, and biotechnology. BlueYard has a diverse portfolio that includes companies such as Bit Bio, Meatable, and Biofidelity, which are involved in biotechnology and healthcare innovations. The firm also invests in blockchain and crypto platforms like Centrifuge and Agnostic, aiming to revolutionize data management and financial systems. The firm's investment strategy emphasizes backing open-ended, breakthrough research and early-stage startups. BlueYard's portfolio companies benefit from its extensive network, strategic guidance, and a supportive investment environment that fosters innovation and growth.

Blumberg Capital is an early-stage venture capital firm that invests in startups from inception through growth stages. With over $650 million in assets under management, the firm focuses on sectors such as fintech, AI, cybersecurity, enterprise software, and digital health. Blumberg Capital has been a key player in supporting companies that use transformative technologies to empower individuals and businesses. Notable investments include Nutanix, BioCatch, and DoubleVerify, demonstrating their success in various tech-driven industries. Additionally, Blumberg Capital has heavily invested in fintech companies, making up about 29% of their portfolio. Key fintech investments include Fundbox, Lendio, and Addepar. The firm is known for its hands-on approach, providing not just capital but also strategic support, leveraging its extensive network and expertise to help startups succeed. Blumberg Capital's investment strategy involves leading seed and Series A rounds, with initial investments ranging from $500,000 to $5 million. They are committed to partnering with visionary entrepreneurs and helping them navigate the challenges of scaling their businesses. The firm operates internationally, with offices in Miami, New York, San Francisco, and Tel Aviv. Their approach and successful track record make Blumberg Capital a prominent player in the venture capital landscape, supporting innovative companies that are shaping the future through technology​.

bmp Ventures is a seasoned venture capital firm based in Berlin, Germany, with over 25 years of experience in early-stage and growth investments. Since its founding in 1997, bmp Ventures has managed 11 venture capital funds and made more than 250 investments, resulting in over 120 exits and more than 20 IPOs. The firm focuses on investing in innovative and scalable companies across various sectors, including digital solutions, industry & deeptech, media & gaming, life sciences & eHealth, cleantech & planet positive, mobility & automotive, and fintech & legaltech​. They typically invest between €350,000 to €3 million in seed and early-stage rounds, with the potential to invest up to €10 million per company through subsequent financing rounds. bmp Ventures is known for being a hands-on investor, providing extensive support to their portfolio companies. This includes strategic advice, networking opportunities, assistance with business model refinement, and guidance on fundraising and exit strategies​.

The Boehringer Ingelheim Venture Fund (BIVF) is a €350 million evergreen corporate venture fund of Boehringer Ingelheim, one of the world's largest family-owned pharmaceutical companies. Founded in 2010 and headquartered in Ingelheim am Rhein, Germany, with additional offices in the United States and China, BIVF invests in groundbreaking, therapeutics-focused biotechnology companies to drive innovation in biomedical research. The fund's capital base has grown substantially since inception, more than doubling through successive expansions that reflect Boehringer Ingelheim's deepening commitment to external innovation. BIVF leads rounds from seed through Series B, deploying checks between $3 million and $30 million, and has built a portfolio of over 40 companies with 6 exits back to the Boehringer Ingelheim parent. The fund's scientific focus spans first-in-class, disease-modifying therapeutics across immuno-oncology, regenerative medicine, infectious diseases, and digital health. The investment thesis prioritizes unprecedented therapeutic concepts addressing high medical need rather than incremental improvements on existing mechanisms. BIVF's evergreen structure distinguishes it from fund-cycle-constrained investors, allowing it to support portfolio companies across the extended development timelines that novel therapeutics require. The fund's global presence across Europe, the US, and China enables it to source and support biotechnology innovation wherever it originates. Portfolio companies benefit from Boehringer Ingelheim's deep expertise in clinical development, regulatory affairs, and pharmaceutical manufacturing — resources that can meaningfully accelerate the translation of early science into approvable therapies.

Boğaziçi Ventures, established in 2015 and headquartered in Istanbul, Turkey, is a venture capital firm focusing on early-stage investments in technology-driven sectors. They target industries such as fintech, health tech, retail tech, and gaming, aiming to support innovative startups that can achieve substantial growth and impact. Notable investments by Boğaziçi Ventures include Cerebrum Tech, a company specializing in digital transformation solutions, and Hiwell, an online therapy platform. They have made 59 investments, primarily within Turkey, but also in regions like the United Kingdom and the United States. The firm is led by co-founders Barış Özistek and Burak Balık, who, along with their team, emphasize sustainable development goals in their investment strategies. Boğaziçi Ventures supports its portfolio companies with not only financial backing but also strategic guidance to help them scale effectively.

BOLD (Business Opportunities for L'Oreal Development) is the global corporate venture capital fund of L'Oreal, the world's largest beauty company. Founded in 2018 and headquartered in Clichy, France, BOLD explores the frontier of beauty through strategic minority investments in promising startups across the beauty value chain. The team of nine includes three Partners and four Principals based in France. The fund leads rounds and has invested across 19 companies with 31 total investments including follow-on rounds. BOLD invests across seed, Series A, and Series B stages with check sizes from $1 million to over $10 million depending on the round. Notable investments include Debut (synthetic biology for cosmetics ingredients, where BOLD led a $40 million Series B), Timeline (a Swiss longevity biotech company that holds the proprietary Mitopure molecule, where BOLD led a $66 million Series D alongside Nestle), Carbios (plastic recycling biotech that IPO'd on Euronext), BORNTOSTANDOUT (fragrance brand), SPARTY (personalized beauty D2C from Japan, invested May 2022), and Live Tinted (personal products, most recent investment February 2026). Gjosa, a water-saving technology company, was acquired. Global Bioenergies also IPO'd from the portfolio. Investment themes span sustainable beauty, clean and natural beauty, health and wellness, beauty tech, green science, data management, and Web3 applications. BOLD's strategic value to portfolio companies extends far beyond capital. Startups gain access to L'Oreal's 110 years of beauty heritage, global R&D capabilities spanning 35 research centers in 10 countries, worldwide distribution infrastructure, and proprietary consumer insights across all beauty categories. This makes BOLD a uniquely strategic partner for founders building at the intersection of science, technology, and beauty.

Bold Capital Partners is a venture capital firm based in Santa Monica, California, with an additional office in Boston, Massachusetts. Founded in 2015 by Peter Diamandis, the firm focuses on investing in groundbreaking technologies and innovative companies that aim to solve humanity's biggest challenges. Their investment strategy targets sectors including advanced robotics, AI, healthcare, and sustainable technologies. Notable portfolio companies include Rugged Robotics, which provides automated construction solutions, and Mighty Buildings, which focuses on sustainable 3D printing for construction. Bold Capital Partners supports startups at various stages, from seed funding to growth stages, emphasizing disruptive potential and significant market impact. The team at Bold Capital Partners includes experienced professionals such as Managing Partner Teymour Boutros-Ghali, General Partner Emilio Diez Barroso, and Operating Partner Helen McBride, who bring a diverse range of expertise in investment and entrepreneurship. They leverage their extensive network and industry knowledge to provide strategic support to their portfolio companies. Bold Capital Partners is committed to uplifting humanity through strategic investments in technologies that democratize and transform major markets​.

Bolt is a pre-seed venture capital firm that invests in startups operating at the intersection of the digital and physical worlds. Founded in 2012, Bolt focuses on companies leveraging innovative technologies and valuable data sets to reimagine products, systems, and experiences. The firm is known for leading the first round of financing in over 90% of its investments, which often include unique hardware and software combinations​. Bolt's portfolio includes notable companies like Tonal, Desktop Metal, Pair Eyewear, and Tive. These companies span various sectors, showcasing Bolt’s commitment to supporting a diverse range of innovative startups​​. The firm operates from Boston, Massachusetts, and is led by experienced partners such as Axel Bichara, Greg McAdoo, Kate McAndrew, Matt Thoms, and Tyler Mincey, all of whom bring extensive backgrounds in venture capital and entrepreneurship. Bolt also engages with the startup community through initiatives like Women in Hardware, a community supporting women and non-binary individuals in hardware development, and Groundwork, a workshop series for direct-to-consumer (DTC) founders.

Brabantse Ontwikkelings Maatschappij (BOM), based in Tilburg, Netherlands, is a venture capital firm dedicated to fostering innovation and economic growth in the Brabant region. Since its founding in 1983, BOM has been actively investing in startups and scale-ups across various sectors including renewable energy, high-tech systems, agro-food, life sciences, and med-tech. BOM has built a significant portfolio with notable investments in companies like Sirius Medical Systems, which enhances cancer treatment with precise surgical solutions, and AvL Motion, known for developing a robotic asparagus harvester. Another key investment is in LionVolt, which focuses on developing sustainable 3D solid-state batteries. BOM is recognized as the most active venture capital investor in Dutch startups, highlighting its commitment to driving economic impact and innovation in the region. Their strategic approach includes providing financial support and expertise to startups, ensuring these companies can grow effectively and sustainably. This proactive involvement has led to successful exits and significant contributions to societal transitions such as climate-neutral energy solutions and advancements in health technology. With a focus on creating a robust entrepreneurial ecosystem, BOM continues to support and invest in companies that have the potential to make substantial contributions to the Brabant economy and beyond.

BOND Capital is a global technology investment firm that focuses on supporting visionary founders throughout their entire innovation and growth lifecycle. Established in 2019, BOND is a spinout of the Kleiner Perkins Digital Growth Fund and was founded by Mary Meeker, along with other key partners. The firm invests in high-growth internet companies, emphasizing long-term partnerships with entrepreneurs who are transforming their industries. Notable investments include prominent companies like Stripe, Canva, and Airbnb. BOND Capital aims to leverage its extensive network and expertise to provide strategic guidance and resources to its portfolio companies. Based in San Francisco, BOND operates with a global outlook, seeking opportunities in diverse markets to support groundbreaking technological advancements​.

Boom Capital, founded in 2016 by Celestine “Cee Cee” Schnugg, is a San Francisco-based venture fund focused on early-stage investments in cutting-edge scientific fields. The firm specializes in deep tech sectors, including healthcare, genomics, machine intelligence, aerospace, and innovative chemistry. Boom Capital's unique value proposition is its deep integration into the scientific community, giving it first access to groundbreaking companies born from frontier science. Leveraging a network of top-tier scientists, including Nobel Prize winners, the firm is positioned to partner with founders long before their ideas are widely recognized. Boom Capital has a track record of identifying transformative technologies early and providing significant support in terms of capital and mentorship. Its portfolio boasts notable companies such as Mammoth Biosciences, Diligent Robotics, Fauna Bio, and A-Alpha Bio, all leaders in their respective fields. The firm has also seen several successful exits, including Planet Labs and Swarm Technologies—the latter being acquired by SpaceX. With a focus on accelerating the journey from research to commercialization, Boom Capital is committed to nurturing the “scientist-protagonists” who are pushing the boundaries of innovation. Its mission is to support high-impact founders with transformative potential, often before traditional investors take notice. By offering not only capital but also access to a vast network of scientific and technical expertise, Boom Capital plays a crucial role in turning visionary ideas into successful ventures.

Boost VC, founded by Adam Draper and Brayton Williams in 2012, is a venture capital firm based in San Mateo, California, that focuses on early-stage investments in frontier technologies. With over $200 million in assets under management, Boost VC typically invests $500,000 in pre-seed startups, supporting over 300 companies. Their portfolio includes notable companies like Coinbase, Protocol Labs, and Snapcard, and spans deep tech sectors such as crypto, VR, AR, AI, space tech, robotics, and bio/health. Boost VC operates a rigorous accelerator program, providing startups with mentorship, resources, and networking opportunities. The three-month program offers intensive support from the Boost VC team and access to a wide network of industry experts and investors. The firm is known for its strong commitment to fostering innovation and diversity within the tech industry, actively supporting women and underrepresented founders. Adam Draper, a fourth-generation venture capitalist, and Brayton Williams, bring extensive experience and a vision for transformative technology startups. The team includes partners like Maddie Callander and Gus Domel, who offer diverse expertise from private aviation to brain health technology.

Bootstrap Venture Partners is a venture capital firm based in Solana Beach, California, founded in 2012 by Jean Balgrosky. The firm draws on more than 40 years of combined team experience in healthcare and technology, bridging the gap between angel investors and traditional VCs. Bootstrap invests $100,000 to $5 million — with a sweet spot around $1.5 million — primarily at seed through Series B, targeting early-stage companies whose products will have meaningful effect on healthcare outcomes or enterprise operations. The firm leads rounds and has made 35 investments. The portfolio has produced one IPO and seven acquisitions, including MD Revolution, Rhombus Energy Solutions, and Immunicon. Active portfolio companies include CirrusMD (virtual care), Scientist.com (research marketplace), Elation Health (clinical EHR), Perceivant, Indigo BioAutomation, and Sinaptica Therapeutics (therapeutic devices, most recent investment in May 2024). The top verticals are enterprise applications, with 15 investments, and healthtech, with 12. Founder and General Partner Jean Balgrosky serves as a board member and operating partner across multiple portfolio companies — functioning as interim CIO in several cases — rather than as a purely passive investor. The entire partner team maintains active governance roles, with the firm's model based on the conviction that early-stage healthcare and technology companies most often fail due to execution gaps, not capital shortfalls.

Borealis Ventures is a venture capital firm based in Hanover, New Hampshire, founded in 2002, with a singular focus on transforming healthcare through new therapies, digital innovation, and enabling technologies. The firm invests in life sciences, digital health, and animal healthcare, typically deploying $250,000 to $750,000 per company. Borealis has made 87 investments across five funds — including the Vox Health Fund — and has achieved 24 portfolio exits. The firm leads rounds and maintains a close relationship with the Dartmouth and Tuck academic ecosystem. Notable exits include Glaukos (medical technology for glaucoma) and Repligen (bioprocessing life sciences). Recent portfolio companies include ASTRA Therapeutics, Jenga Biosciences, Triveni Bio, and OvaInnovations (exit recorded November 2024). The data-driven, thematic approach has produced over 50 executed deals across multiple healthcare sub-verticals. Borealis is led by co-founder and Partner Phil Ferneau, who leads healthcare investing, alongside Partners Ben Shaw and Julia Stephanus. The team's collective background in healthcare investment and proximity to New England's research institutions enables early access to academic spinouts and clinician-founded companies at the pre-institutional stage. Borealis places particular emphasis on backing founders who are advancing genuinely differentiated science or platform technologies, rather than incremental product improvements.

Borski Fund is a pioneering venture capital firm based in Amsterdam that focuses on closing the gender gap in venture capital by investing in companies led by women or gender-diverse teams. Founded in 2019 by Simone Brummelhuis and Laura Rooseboom, Borski Fund is named after Johanna Borski, a 19th-century Dutch financier who was instrumental in funding the Dutch Central Bank. The fund is dedicated to supporting female entrepreneurs and teams with at least one female executive with equity stakes, aiming to foster innovation, inclusivity, and economic growth. Borski Fund’s investment thesis is centered around the belief that diversity leads to better decision-making and stronger business outcomes. The fund’s portfolio includes companies across various sectors, including technology and sustainability, with a particular focus on those driven by data and AI. Borski Fund also stands out due to its collaboration with major partners like the Visa Foundation, which recently contributed to expanding the fund to €40 million. This partnership reflects a shared commitment to promoting gender equality in the startup ecosystem, and the fund has made significant strides in empowering women-led businesses across Europe. By creating opportunities for women and gender-diverse teams, Borski Fund is not only addressing the significant investment gap in venture capital but also championing a more equitable and inclusive business environment.

Bossanova Investimentos, often referred to as Bossanova Invest, is a prominent venture capital firm based in Brazil, specializing in pre-seed stage investments. Founded in 2011 by Pierre Schurmann and later joined by João Kepler, Bossanova has established itself as the most active micro-VC in Latin America. The firm focuses on B2B and B2B2C technology companies that are innovative, digital, and scalable​​. Bossanova has invested in over 1,200 startups across more than 1,000 companies, making it a significant player in the early-stage investment scene. Their portfolio includes notable exits such as Glovo, Upsie, and Shift​​. They employ a rigorous selection process and offer extensive support to their portfolio companies to ensure rapid growth and success. The firm's investment strategy revolves around startups that are over 1.5 years old, have found a problem-solution fit, and are already operational and generating revenue. They avoid investments in sectors that exclusively target government, e-commerce, games, or hardware that competes with existing portfolio companies​. Bossanova's network includes over 10,000 co-investors, founders, and partner companies, providing a robust ecosystem for startups to thrive. They also offer educational resources through platforms like Clubb.vc, which provides courses and materials on investment, innovation, and business development​​. In addition to traditional equity investments, Bossanova has introduced an innovative investment model via Cédula de Crédito Bancário (CCB), which allows investors to gain exposure to the startup ecosystem with capital protection and fixed returns​​. This approach aims to democratize access to venture capital investments, making it accessible to a broader range of investors.

Boulder Ventures, established in 1995, is a venture capital firm that focuses on investing in early-stage information technology and life sciences companies. With headquarters in Boulder, Colorado, and an office in the Mid-Atlantic region, the firm leverages decades-long relationships with entrepreneurs and investors to drive its investment strategy. Boulder Ventures has raised eight funds totaling approximately $429 million, with the most recent fund, Boulder Ventures VIII, closing at $58 million in 2022. The firm has a notable track record, having invested in 61 companies, leading to 28 exits and 10 IPOs​. Key investments by Boulder Ventures include companies like Array BioPharma (acquired by Pfizer for $11.8 billion), LeftHand Networks (acquired by HP), and Wall Street on Demand (acquired by Goldman Sachs). The firm’s portfolio is diverse, covering sectors such as software, IT services, storage and communications, and life sciences. Kyle Lefkoff, the founder and general partner, brings over 38 years of venture capital experience. His extensive background includes significant roles in guiding companies through critical growth stages and strategic exits​.

Boundary Capital is a London-based venture capital firm focused on impact investing in early-stage companies that aim to improve lives and deliver strong commercial returns. Their investment strategy centers on technologies in life sciences, engineering, and data science that address critical global challenges such as healthcare, sustainability, and education. By aligning economic success with positive societal impact, Boundary Capital looks for businesses that offer innovative solutions to real-world problems. The firm typically invests in businesses from late seed to Series B stages, targeting returns of 3x within five to seven years. They place a strong emphasis on companies with proven economic potential and intellectual property advantages. Their portfolio includes high-growth companies like Glyconics, which is developing diagnostics for chronic lung diseases, and Echion, which focuses on fast-charging battery technology. Boundary's team combines extensive entrepreneurial and investment expertise. Led by Managing Partner Dan Somers, the firm supports portfolio companies with strategic guidance, leveraging both their financial investment and hands-on operational support.

Bow Capital, established in 2016 and based in Menlo Park, California, is a venture capital firm that leverages its strong connection with the University of California system to access a rich ecosystem of academic and research resources. This partnership provides them with broad access to the UC's 2.6 million faculty, staff, students, and alumni, as well as numerous research centers and medical facilities​. Bow Capital invests primarily in early-stage startups, focusing on sectors such as artificial intelligence, machine learning, big data, and enterprise software. Their portfolio includes notable companies like Ambi Robotics, Heartex, and Linus Biotechnology. The firm aims to bridge the gap between academia and industry, helping to commercialize innovative technologies and scientific discoveries. The investment strategy at Bow Capital includes participating in pre-seed, seed, and Series A funding rounds. They emphasize not only financial support but also strategic guidance and operational expertise, leveraging their network of Silicon Valley founders and industry leaders to help startups grow and succeed​. Notable exits for Bow Capital include companies like RealtyShares, Rimeto, and Skylight, reflecting their ability to identify and nurture high-potential startups to successful outcomes.

BoxGroup is a prominent early-stage venture capital firm based in New York City, established in 2009 by David Tisch and Adam Rothenberg. The firm focuses on investing in pre-seed to Series A rounds, targeting sectors such as consumer technology, enterprise software, fintech, healthcare, life sciences, and marketplaces. BoxGroup has built a robust portfolio with notable investments in companies like Plaid, Airtable, Ro, Ramp, Warby Parker, and Harry’s. They are known for their early-stage support and have made over 600 investments, actively backing innovative startups with the potential to disrupt and define new market categories. BoxGroup typically invests between $50,000 to $250,000 per deal, emphasizing conviction in the founding teams they support. Their approach is geography-agnostic, although they have a strong presence in key tech hubs such as New York, Silicon Valley, and Los Angeles. The firm has also seen several successful exits, including high-profile IPOs and acquisitions. They aim to be one of the earliest and most supportive investors, providing strategic guidance and leveraging their extensive network to help startups grow and succeed.

BoxOne Ventures, established in 2018 and based in Montreal, Canada, is a venture capital firm that focuses on early-stage investments across diverse and impactful sectors. The firm invests in companies with strong technology platforms in areas such as biotechnology, computational biology, AI and data analytics, digital health, fintech, and food technology. BoxOne Ventures has built a robust portfolio featuring notable investments like Juvena Therapeutics, which raised $41M to advance therapeutic solutions. Other significant investments include companies like dfuse, a blockchain development platform, and Odd Burger, a plant-based fast food chain. The firm’s strategy includes backing talented entrepreneurs and innovative technologies that aim to make a positive difference globally. The team at BoxOne Ventures comprises experienced founders and investors who are deeply involved in the development and support of their portfolio companies. This hands-on approach helps startups navigate the challenges of scaling and achieving market success.

New Science Ventures (NSV), founded in 2004, is a venture capital firm that focuses on investments in life sciences and information technology. With offices in New York and London, NSV aims to leverage breakthrough science to create significant value. The firm has a diverse portfolio, investing in companies that utilize fundamental, science-based innovations to address large unmet needs. NSV's notable investments include Ventyx Biosciences, which raised $114 million to advance its pipeline of immunology programs, and Paragraf, a company that mass-produces graphene electronics. Other significant portfolio companies are Phase Four, which develops next-generation electric propulsion solutions for satellites, and NorthSea Therapeutics, which focuses on novel treatments for liver-related diseases​. The firm typically invests in early to mid-stage companies and supports them through crucial value inflection points to help them scale. Their investment strategy is grounded in strong intellectual property protection and a long-term view​.

Braemar Energy Ventures, founded in 2002, is a New York-based venture capital firm with a strong focus on energy technology and innovation. Notable investments include ChargePoint, Getaround, and Metalenz, showcasing their dedication to transformative energy and tech sectors. They are particularly interested in energy technology, mobility, power, and infrastructure, with a geographic focus primarily on the United States. Braemar's investment strategy revolves around early to mid-stage funding, often leading rounds with substantial check sizes, as seen in Getaround’s $140 million Series E. The firm prides itself on being an active investor, often leading investments and working closely with entrepreneurs to navigate the complexities of the energy transition. Key team members include co-founders William Lese and Neil Suslak, who bring extensive experience and industry connections. Braemar Energy Ventures has a robust track record, with 19 exits including prominent companies like ChargePoint and Viridity Energy. They are approachable for startups looking for engaged and knowledgeable partners in the energy sector, typically through direct networking and industry events. Braemar's team, based mainly in New York, leverages their deep industry expertise to identify and support promising ventures, aiming to drive significant environmental and societal impact through their investments. For startups, aligning with Braemar’s focus on innovation and sustainability in energy technology is key to capturing their interest and securing funding.

Bread and Butter Ventures, based in Minneapolis, Minnesota, is an early-stage venture capital firm that invests globally while leveraging the region's strong corporate connections and industry expertise. Founded in 2017, the firm focuses on several key sectors including health tech, food tech, and enterprise SaaS. Their portfolio includes notable investments such as Ducky, an automation and workflow software company; Chiyo, which focuses on food and agriculture technology; SocialCrowd, a platform for enterprise applications; and Nest Collaborative, a health tech company providing virtual lactation support. They have made a total of 87 investments, emphasizing their active involvement in the startup ecosystem. Bread and Butter Ventures has also seen successful exits, including Upsie, a technology company that was acquired, and Spoonshot, which was also successfully exited. The firm is led by Managing Partners Brett Brohl and Mary Grove, who bring extensive experience in technology and early-stage investing.

Break Off Capital is a forward-looking venture capital firm that focuses on funding early-stage companies at the cutting edge of technology. With a mission to "fund the future," the firm actively seeks out innovative projects that have the potential to disrupt traditional industries and drive significant technological advancements. Their investment strategy centers on emerging sectors such as quantum computing, artificial intelligence, and other transformative tech domains that promise to reshape the way industries operate. The fund typically supports ventures in their formative stages, providing not only capital but also strategic insights to help startups scale and navigate competitive landscapes. Break Off Capital emphasizes long-term partnerships, working closely with entrepreneurs to refine business models, accelerate product development, and access broader markets. By leveraging their vast network, they help connect portfolio companies with essential resources, strategic partners, and additional investors. The team at Break Off Capital consists of seasoned professionals with diverse backgrounds in finance, technology, and strategic consulting. Key figures include senior adviser Ian, who brings extensive experience from his time at Eastdil, where he co-founded the Hong Kong office and honed his expertise in global capital markets. The team’s collective experience and strategic acumen enable them to identify high-potential ventures and provide the necessary support to turn visionary ideas into reality. Through a blend of capital investment, strategic mentorship, and industry connections, Break Off Capital is committed to backing ventures that are poised to lead the future of technology and innovation​.

Break Trail Ventures is an early-stage venture capital firm based in Columbus, Ohio, and Boulder, Colorado. Founded in 2018, the firm focuses on investing in startups that are innovating in sectors such as consumer products, advanced manufacturing, big data, digital health, e-commerce, mobile, SaaS, and the Internet of Things. The firm has built a diverse portfolio that includes notable companies like Cotopaxi, an outdoor gear brand committed to sustainability; Oiselle, a women's athletic apparel company; and Pepper, a lingerie brand designed for smaller cup sizes. Break Trail Ventures aims to support entrepreneurs who are pioneering new paths in their industries, emphasizing a customer-first approach and solving significant problems. Break Trail Ventures operates with a mission to partner closely with founders, providing not only capital but also strategic guidance to help startups achieve product-market fit and scale effectively. The firm is led by Managing Partner Jay Hirsh, who brings extensive experience in venture capital and entrepreneurship..

Breakout Labs, founded in 2012 as part of the Thiel Foundation, is an incubator and venture fund that supports early-stage, deep science companies with radical and emerging technologies. The fund provides up to $350,000 in initial funding and extensive support for startups that are too speculative for traditional venture capitalists. Breakout Labs focuses on companies at the intersection of technology, biology, materials, and energy, aiming to transition groundbreaking scientific discoveries from the lab to the market​. Notable portfolio companies include SciBac, which targets antibiotic-resistant diseases through microbiome science, and Azitra, which leverages the skin’s microbiome to treat skin diseases. Other innovative investments include ZymoChem, which develops sustainable chemical production processes, and EpiBone, which grows custom bones using 3D imaging and stem cells​. Breakout Labs has a history of significant follow-on funding for its portfolio companies, totaling over $1 billion. This success underscores their commitment to supporting the entire lifecycle of their investments, from seed to scale. The team, led by Managing Partners Lindy Fishburne and Julia Moore, includes experts who provide strategic guidance and leverage a vast network of founders, corporate partners, and advisors.

Breakout Ventures is a San Francisco-based venture capital firm founded in 2016, focused on early-stage investments in creative bioscience companies. The firm is dedicated to supporting startups that leverage the convergence of biology, chemistry, and technology to develop bio-based solutions aimed at improving human health and sustainability​. Breakout Ventures has raised significant capital, including a $112.5 million Fund II, to back innovative companies at the intersection of technology and biology. Their investment portfolio includes companies like Immusoft, which is working on genetically modifying B cells for sustained therapeutics, and Checkerspot, which uses synthetic biology to produce bio-derived oils​. The firm's investment strategy targets areas such as synthetic biology, cell and gene therapy, biomanufacturing, and carbon transformation, supporting companies from seed to scale. Notable portfolio companies include Cytovale, which focuses on diagnosing immune-mediated diseases, and Ecovative Design, which uses mycelium technology for sustainable materials. The Breakout Ventures team, led by managing partners Lindy Fishburne and Julia Moore, brings extensive experience in supporting science-driven companies. The firm originated from Breakout Labs at the Thiel Foundation, which has a strong history of advancing early-stage deep science startups​.

Breakthrough Energy Ventures, part of the Breakthrough Energy network founded by Bill Gates, focuses on financing and scaling companies that aim to eliminate greenhouse gas emissions globally. With over $3.5 billion in committed capital, BEV invests in more than 110 cutting-edge companies across various stages, from seed to growth. The firm targets technologies capable of significantly reducing greenhouse gases, aiming for at least half a gigaton reduction annually. Key areas of investment include clean hydrogen, long-duration energy storage, sustainable aviation fuel, direct air capture, and green manufacturing. BEV supports companies like H2Pro, which innovates in green hydrogen production, and Heirloom, focused on cost-effective carbon removal. BEV’s strategy involves more than just funding; it provides comprehensive support, including technical, operational, market, and policy expertise to help companies overcome scaling challenges. This holistic approach ensures that new climate technologies can transition from development to widespread commercial adoption. The team at BEV includes experts like Eric Toone, Technical Lead of the Investment Committee, and Megan Wenrich, Vice President of Development. These professionals bring a wealth of knowledge and experience to guide the firm’s investments and initiatives.

Breyer Capital is a premier venture capital firm founded by Jim Breyer in 2006. The firm focuses on catalyzing high-impact entrepreneurs across various sectors, including artificial intelligence, digital health, and fintech. Notable investments from Breyer Capital include Facebook, Spotify, 23andMe, and Zoox, with Zoox being acquired by Amazon. Breyer Capital invests in early-stage startups, particularly those in the AI, healthcare, and consumer tech industries. The firm's approach is founder-centric, emphasizing long-term partnerships and hands-on engagement. They typically participate in pre-seed, seed, and Series A funding rounds. Geographically, Breyer Capital has a broad focus, investing in companies across the United States, Europe, and beyond. The firm is headquartered in Menlo Park, California, but also has a significant presence in Austin, Texas. Key figures at Breyer Capital include founder Jim Breyer and partner Daniel Breyer. The team is known for its deep industry connections and strategic guidance, supporting portfolio companies with both capital and mentorship. Breyer Capital's recent investments include Atropos Health, Nimble Robotics, and Elemental Cognition, highlighting their commitment to innovative solutions in AI and healthcare. The firm's long-term vision and robust support structure make it a vital player in the venture capital landscape.

BrightEdge Fund is the philanthropic impact investment arm of the American Cancer Society (ACS), established in 2019. Headquartered in Kennesaw, Georgia, BrightEdge focuses on accelerating the commercialization of innovations in cancer care. The fund aims to reduce cancer mortality, alleviate pain and suffering, and advance health equity by investing in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, and technologies. Notable investments in BrightEdge’s portfolio include Checkmate Pharmaceuticals, an immunotherapy drug developer; Freenome, a biotech company specializing in early cancer detection through liquid biopsy; and TailorMed, which provides patient financial navigation software. The fund has also invested in Catena Biosciences and Clasp Therapeutics. BrightEdge has a strong track record of exits, with companies like Castle Biosciences going public and Tmunity being acquired. The fund leverages the ACS’s extensive research and expertise to mitigate risks associated with health science investments. This affiliation allows BrightEdge to provide valuable insights into the competitive landscape and regulatory environment, enhancing the potential for successful commercialization of its portfolio companies​. Managed by a team of experienced professionals, including Managing Director Alice Pomponio, BrightEdge also serves as a follow-on investor and board observer, working alongside prominent venture capital firms to support its mission. The fund’s current fundraising target is $100 million, aiming to sustain ACS’s life-saving programs and further its impact.

BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), founded in 2018 and based in Kennesaw, Georgia. A donor-funded philanthropic impact fund, BrightEdge invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, medical devices, and enabling technologies. Through the end of 2024, the fund has deployed $52 million across 22 companies, with 15 active portfolio companies holding potential to impact 13.4 million patients. The fund invests globally — across the United States, Canada, Europe, and Asia-Pacific. Investments are aligned with ten American Cancer Society mission priority areas, including cancer health equity, patient survivorship, disease prevention, clinical trial accessibility, and care quality. Recent portfolio companies include Signify Bio (in vivo therapeutics, 2024). BrightEdge also runs the BrightEdge Entrepreneurs program to support founders navigating the early stages of cancer innovation. Managing Director Alice Pomponio brings experience from Red Sky Partners and teaches biomedical innovation at MIT; Director of Investments Lucas de Breed leads deal sourcing and execution. BrightEdge distinguishes itself from pure financial investors by reinvesting all financial returns back into the American Cancer Society's scientific and patient advocacy programs, making every exit outcome directly compound the mission. The fund operates with a dual mandate: achieving genuine venture returns while ensuring the ACS remains a financially self-sustaining engine for cancer research for decades ahead.

Brightlands Venture Partners is a venture capital firm based in Geleen, Netherlands, with a strong focus on investing in startups and scale-ups that address key societal challenges in sustainability and health. Established in 2014, the firm manages several funds, including Brightlands Agrifood Ventures, BVP Fund IV, Chemelot Ventures, and Limburg Ventures, with a combined capital of approximately €120 million. The firm primarily invests in sectors like renewable chemistry, regenerative medicine, agri-food, and digital technologies, aiming to support companies that contribute to a sustainable and healthier future. Brightlands Venture Partners has a diverse portfolio of over 70 companies, including Qorium, a pioneer in cell-cultured leather, and PL BioScience, a leader in sustainable cell culture media. Their investment strategy is not only about providing capital but also involves active involvement and support in scaling the companies, leveraging their deep sector expertise. The leadership team at Brightlands includes experienced professionals like Casper Bruens, Marcel Kloosterman, and Kim de Boer, who collectively bring decades of experience in venture capital and the life sciences industry. Their approach is characterized by a strong emphasis on impact investing, aligning financial returns with measurable societal impact.

Brightstone Venture Capital is a venture capital firm based in Minneapolis, Minnesota, established in 1985. The firm focuses on early-growth stage investments in technology and life sciences sectors. With a strong track record, Brightstone manages multiple venture partnerships and currently oversees a $100 million fund aimed at supporting innovative startups. Brightstone's portfolio includes notable companies like VRChat, Celcuity, Bite Squad, and StemoniX, which have achieved significant milestones such as IPOs and major acquisitions. For instance, Bite Squad was sold to WAITR Holdings for $321 million, and StemoniX went public on NASDAQ under the ticker VYNT. The firm is led by experienced partners, including David Dalvey, Jeffrey Cowan, and Patrick O'Shaughnessy, who bring deep expertise in venture investing and entrepreneurship. Brightstone is known for its hands-on approach, providing strategic guidance and operational support to help portfolio companies scale and succeed. Brightstone Venture Capital has made 62 investments and has had 25 successful exits, showcasing their ability to identify and nurture high-potential startups. Their investments span various industries, including biotechnology, software, virtual reality, and medical technology​.

Brigus Capital is a venture capital firm focused on investing in early-stage startups with the potential for significant growth. The firm typically targets companies that are innovating within their respective industries and have the capability to scale rapidly. Brigus Capital's investment strategy is characterized by a hands-on approach, where the firm not only provides capital but also leverages its network and expertise to help portfolio companies navigate challenges and achieve their growth objectives. Based in New York, Brigus Capital emphasizes investments in sectors such as technology, healthcare, and consumer products. The firm seeks out companies that are at the forefront of innovation, particularly those with strong leadership teams and scalable business models. Brigus Capital's portfolio is diverse, reflecting its broad investment thesis and commitment to backing transformative companies. The team at Brigus Capital is composed of experienced investors and industry veterans who bring a wealth of knowledge and expertise to the table. This experience allows them to offer valuable strategic guidance and operational support to their portfolio companies, helping them to accelerate growth and achieve their long-term goals. Overall, Brigus Capital is dedicated to supporting the next generation of industry leaders, with a focus on fostering innovation and driving economic growth through its investments. The firm's commitment to its portfolio companies extends beyond financial backing, making it a valuable partner for startups looking to scale and succeed in competitive markets.

Broadview Ventures, founded in 2008 and headquartered in Boston, Massachusetts, is a venture capital firm focused on investing in early-stage life sciences companies. The firm specializes in cardiovascular and neurovascular diseases, aiming to bridge the translational gap between scientific research and clinical application. Broadview Ventures has a robust portfolio that includes companies such as DecImmune Therapeutics, which develops therapies to mitigate injury post-myocardial infarction, and FineHeart, a French medical device company creating innovative cardiac support technologies. Other notable investments include GI Windows, developing non-surgical approaches for treating chronic diseases, and Adient Medical, focusing on absorbable medical devices. The firm has made 79 investments and achieved several successful exits, including Cardialen, VentriNova, and Renovacor. Broadview's investment strategy leverages their extensive industry expertise and network to support companies from seed through later stages of development. Broadview Ventures is led by a team of experienced professionals dedicated to advancing healthcare through innovative solutions. Their strategic focus and targeted investments aim to address unmet medical needs, ultimately improving patient outcomes and advancing the field of cardiovascular and neurovascular health.

Brooklyn Bridge Ventures (BBV), founded in 2012 by Charlie O'Donnell, is a pioneering early-stage venture capital fund based in Brooklyn, New York. BBV primarily focuses on leading or co-leading pre-seed and seed rounds, targeting startups in the New York City area that have raised less than $750,000 in prior funding rounds. BBV has a diverse portfolio, investing in sectors such as B2B SaaS, eCommerce, Fintech, Foodtech, and Healthcare. Some of their notable investments include Hungryroot, Brigit, and Yuvo Health. These companies have seen significant growth and success, reflecting BBV's ability to identify and nurture promising startups. The firm is known for fostering a strong community among founders and professionals, providing extensive support and guidance to early-stage startups. They typically invest around $350,000, focusing on companies with well-researched ideas, working prototypes, or early traction with users or revenue. As of May 2023, BBV announced that it would no longer be making new investments. Despite this, the firm continues to support its existing portfolio companies, helping them navigate growth and sustainability challenges. For startups seeking engagement, BBV's legacy emphasizes the importance of strong preparation and clear demonstration of potential.

Btomorrow Ventures (BTV) is the corporate venture capital arm of British American Tobacco, established in 2020 and headquartered in London. BTV focuses on building transformative and innovative businesses across sectors such as consumer brands, digital transformation, new technologies, and future sciences, with a strong emphasis on Environmental, Social, and Governance (ESG) criteria. BTV has made notable investments in startups like FlexSea, a UK-based company pioneering sustainable, seaweed-derived bioplastics, and Open Book Extracts, a cannabinoid innovation house in North Carolina. Their portfolio includes diverse companies such as Awake Chocolate in Canada, offering functional caffeinated chocolates, and Hesperos in Florida, known for their Human-on-a-Chip® technology​. The firm typically participates in early to growth-stage funding, with an average check size of $1 million. BTV is known for leading investment rounds and has a keen interest in companies that align with their sustainability and innovation goals. They actively collaborate with their portfolio companies through initiatives like Btomorrow Labs, providing strategic support and global distribution channels. Led by Managing Director Juan Palacios, the BTV team operates primarily from London, offering a blend of financial investment and strategic partnerships to accelerate the growth of ambitious founders and their disruptive technologies.

Buckley Ventures, founded in 2020 by Joshua Buckley and based in San Francisco, focuses on early-stage venture capital investments. The firm has made 35 investments across various sectors including hardware, software, and fintech. Notable investments include Rain AI, a company in the hardware industry; Framework, which specializes in consumer electronics; and Symbolica AI, a firm developing artificial intelligence solutions. Buckley Ventures has also invested in NexHealth, a healthcare software company, and Porter Finance, a trading platform. The firm has seen successful exits from companies like Whereby and ScienceIO. The team, led by Joshua Buckley and supported by Jonathan Choi and Paul Barnes, emphasizes supporting innovative startups with strong growth potential. Buckley Ventures aims to back companies that are poised to make significant impacts in their respective fields, leveraging their expertise and network to help these startups scale effectively.

Bullpen Capital, established in 2010, is a venture capital firm based in San Francisco that specializes in post-seed investments. Their focus is on startups that have found product-market fit but are often overlooked by traditional venture capital due to various factors such as market size or early-stage revenue metrics. Bullpen Capital has funded over 100 companies, leveraging their expertise to help these businesses achieve significant milestones within a short period. Notable investments by Bullpen Capital include companies like FanDuel, Grove Collaborative, and Life360, all of which have achieved notable exits. Other significant portfolio companies include IPSY, Braze, and Carbon Health, reflecting their diverse investment strategy across consumer products, enterprise software, health tech, and more. The team at Bullpen Capital includes experienced professionals like co-founder Paul Martino and partners Eric Wiesen and Richard Melmon. Their combined experience spans across various industries and operational roles, providing portfolio companies with robust support and strategic guidance. Bullpen Capital continues to focus on sectors such as e-commerce, health, and enterprise applications, ensuring their portfolio companies receive the necessary resources and mentorship to scale effectively.

Burst Capital is an early-stage venture capital firm founded in 2017 by Geoff Donaker, a former COO of Yelp. The firm is based in Palo Alto, California, and focuses primarily on investing in pre-seed, seed, and Series A rounds, particularly in software, SaaS, fintech, and enterprise sectors. The team includes experienced leaders from Yelp and other major tech companies, offering deep industry knowledge and hands-on support for startups. Burst Capital’s portfolio includes notable companies like Sourcegraph, Handshake, and Ada, with several achieving unicorn status. The firm is known for investing in high-growth tech startups and has been involved in over 120 investments to date. They maintain a lean but experienced team of partners, including Wendy Lim and Rob Krolik, who bring expertise in scaling companies and taking them public. Burst Capital primarily invests in U.S.-based companies but also backs global startups. Their investment strategy is founder-focused, leveraging their operational experience to guide startups from early stages to growth​.

Business Finland is a public organization under the Finnish government that aims to support innovation, economic growth, and sustainable development in Finland. Established in 2018 from a merger between Tekes (the Finnish Funding Agency for Innovation) and Finpro (an export and investment promotion agency), Business Finland offers various services including innovation funding, internationalization support, and investment promotion. Its mission is to accelerate the global success of Finnish companies while positioning Finland as a competitive and attractive destination for foreign investments. Business Finland plays a significant role in promoting Finnish industries globally, particularly focusing on sectors like ICT, cleantech, bioeconomy, health, and digitalization. The organization is also deeply committed to sustainability, which is central to its strategy through 2025. It works to foster collaboration between research institutions, businesses, and international stakeholders, driving systemic change in addressing global challenges like climate change. Additionally, Invest in Finland, a key branch of Business Finland, actively attracts foreign direct investment, helping foreign companies explore opportunities in Finland. This initiative strengthens local ecosystems, creating thousands of jobs annually, particularly in high-growth sectors. With over 760 specialists spread across 40 international locations and 16 offices in Finland, Business Finland remains a cornerstone in fostering innovation and economic development within Finland's vibrant tech ecosystem.

Butterfly Ventures, established in 2012, is a leading seed-stage venture capital firm based in Helsinki, Finland, with additional offices in Oulu, Stockholm, Tallinn, and Copenhagen. The firm focuses on deep tech and hardware startups in the Nordics and Baltics. Their investment portfolio includes companies such as Wolt and Supercell, showcasing their commitment to backing transformative technology companies. Butterfly Ventures typically invests in pre-seed, seed, and early-stage rounds, with check sizes ranging from €100,000 to €2 million. They emphasize sustainable and science-based innovations, aligning with the EU's Article 8 and Sustainable Finance Disclosure Regulation (SFDR). Their latest fund, Butterfly Venture Fund IV, raised an initial €47 million, aiming for a total of €100 million to support groundbreaking startups across the region. The team at Butterfly Ventures includes experienced professionals like Juho Risku, co-founder and partner, who has a strong background in digital technologies and entrepreneurship. Other key members include Ville Heikkinen, known for his expertise in VC financing and M&A, and Tanya Horowitz, who brings a wealth of experience from her background in asset management and M&A investment banking in New York. Butterfly Ventures is deeply integrated into the Nordic startup ecosystem, actively seeking companies that have the potential for significant societal, environmental, and economic impact. Startups looking to partner with Butterfly Ventures should focus on innovative solutions that address major global challenges, particularly in deep tech and hardware sectors.

Byers Capital, managed by Blake Byers, is a San Francisco-based family office that focuses on early-stage investments in technology and biotech sectors. Founded in 2021, the firm has quickly established a diverse portfolio, including investments in high-profile companies like Neuralink, NewLimit, and Benchling. Byers Capital is known for its strategic investments in Series A and B rounds, particularly in the healthcare and enterprise applications sectors. The firm primarily invests in the United States but has also made select international investments, such as in the Netherlands. Byers Capital leverages Blake Byers' extensive experience as a former partner at Google Ventures, where he was involved in several successful exits, including companies like Robinhood and Grail. This deep expertise in both venture capital and scientific research allows Byers Capital to support its portfolio companies with not just capital, but also strategic guidance and industry connections​.

C4 Ventures is a distinguished European venture capital firm established in 2012 by Pascal Cagni, a former Apple executive, with offices in Paris and London. The firm specializes in early to mid-stage investments in technology-driven startups, particularly those targeting expansion into European markets. C4 Ventures’ impressive portfolio includes notable investments in companies such as Graphcore, Riskified, and Foursquare. They are recognized for their strategic support and capital, which have been pivotal in helping businesses like Anki and Clippings scale successfully. The firm focuses on sectors including consumer hardware, digital media, and e-commerce, with recent investments in innovative companies like VoltR and Refurbed. C4 Ventures typically leads funding rounds and offers hands-on assistance to their portfolio companies, leveraging the extensive industry experience of their team, including co-founder Boris Bakech and partner Michel Sassano. For startups aiming to engage with C4 Ventures, it's essential to demonstrate a clear path to market leadership and scalability. The firm values innovative approaches and strong market potential, evidenced by their active investment and exit strategies, including significant exits like Riskified and Trouva.

Caffeinated Capital is an early-stage venture capital firm founded in 2013 by Raymond Tonsing and based in San Francisco, California. The firm focuses on investing in transformative technology companies from inception and supporting them throughout their growth stages. Caffeinated Capital has a diversified portfolio across sectors such as consumer, healthcare, fintech, defense, and cryptocurrency. Notable investments include companies like Affirm, Pluto, and Gigster, with exits such as Zoox (acquired by Amazon) and CTRL-Labs (acquired by Meta). The firm has a strong track record of backing successful startups that later attract significant follow-on funding from other major investors. Caffeinated Capital typically invests in pre-seed, seed, and Series A rounds, with an average check size ranging from $2 million to $12 million. The firm is highly selective, often partnering with founders who demonstrate a unique vision and the resilience to bring transformative ideas to fruition. The team at Caffeinated Capital, led by Raymond Tonsing, is known for its hands-on approach, providing strategic guidance, mentorship, and leveraging its extensive network to support portfolio companies. The firm has a global investment outlook but maintains a strong presence in major US tech hubs, particularly San Francisco.

Caixa Capital Risc, established in 2004 and based in Barcelona, Spain, is the venture capital arm of CriteriaCaixa. The firm focuses on investing in innovative companies at their initial and growth stages, particularly in Spain and Portugal. Caixa Capital Risc specializes in three main areas: Information Technology, Life Sciences, and Industrial Technologies. The firm typically invests in rounds ranging from pre-seed to Series B, with investment amounts varying from $500,000 to $5 million. Notable sectors they invest in include analytics, AI, cloud infrastructure, developer tools, edtech, fintech, healthcare services, and robotics. Their extensive portfolio includes companies like Build38, MedLumics, and Recognai, showcasing their diverse investment interests. Caixa Capital Risc is committed to supporting its portfolio companies not only financially but also through strategic guidance and leveraging its extensive network. They have a history of successful exits and are considered a key player in the Spanish and Portuguese startup ecosystems.

Calculus Capital, founded in 1999 by John Glencross and Susan McDonald, is a UK-based venture capital firm focusing on Enterprise Investment Schemes (EIS) and Venture Capital Trusts (VCT). The firm invests in early-stage companies in high-growth sectors such as technology, healthcare, and entertainment. The Calculus VCT offers a diversified portfolio of 30-40 UK companies, providing development and scale-up capital. Investors benefit from tax-efficient opportunities, including 30% income tax relief and tax-free capital gains and dividends if shares are held for at least five years. The Calculus EIS Fund targets Knowledge Intensive Companies, offering similar tax benefits and aiming for a return of £2 for every £1 invested. Calculus Capital is known for its strategic, hands-on approach, supporting companies with strong business models and significant growth potential. The firm's experienced team from leading financial institutions ensures robust support and guidance, contributing to successful exits like those to Microsoft and SAP.